ArticlePLoS neglected tropical diseases2025
Microplanning improves stakeholders' perceived capacity and engagement to implement lymphatic filariasis mass drug administration.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inclusion in Neglected Tropical Disease Programmes: A Review of Inclusive Approaches for Control and Elimination.Healthcare (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAchieving adequate mass drug administration (MDA) coverage for lymphatic filariasis is challenging. We sought to improve stakeholder engagement in MDA planning and increase subsequent MDA coverage through a series of microplanning workshops. METHODOLOGY: Prior to the 2018 MDA, Haiti's Ministry of Public Health and Population (MSPP) and partners conducted 10 stakeholder microplanning workshops in metropolitan Port-au-Prince. The objectives of the workshops were to identify and address gaps in geographic coverage of supervision areas (SAs); review past MDA performance and propose strategies to improve access to MDA; and review roles and responsibilities of MDA personnel through increased stakeholder engagement. Retrospective pre-testing was employed to assess the effectiveness of the workshops. Participants used a 5-point scale to rank their understanding of past performance, SA boundaries, roles and responsibilities, and their perceived engagement by MSPP. Participants simultaneously ranked their previous year's attitudes and their attitudes about MDA following the 2-day microplanning workshop. Changes in pre- and post-scores were analyzed using Wilcoxon signed-rank tests. PRINCIPAL
findingsA total of 356 stakeholders across five communes participated in the workshops. Participants conducted various planning activities, including revising SA boundaries to ensure full geographic reach of MDA, proposing or validating social mobilization strategies, and proposing other MDA improvements. Compared with previous year rankings, the workshops increased participant understanding of past performance by 1.34 points (standard deviation [SD] = 1.05, p <0.001); SA boundaries by 1.14 points (SD = 1.30; p <0.001); their roles and responsibilities by 0.71 points (SD = 0.95, p <0.001); and sense of engagement by 1.03 points (SD = 1.08, p <0.001). Additionally, compared with 2017, drug coverage increased in all five communes during the 2018 MDA. CONCLUSIONS/SIGNIFICANCE: Participatory stakeholder workshops during MDA planning can increase self-reported engagement of key personnel and may improve staff performance and contribute to achievement of drug coverage targets. Microplanning success was supported by MDA results, with all communes achieving preset MDA coverage targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.